Document Detail

The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women.
MedLine Citation:
PMID:  8002685     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: While observational studies have suggested that unopposed estrogens reduce the incidence of coronary disease in postmenopausal women, there are few data on the effect of combined therapy with estrogens and progestins--a regimen adopted in recent years to minimize the risk of endometrial hyperplasia and cancer. In clinical trials, the addition of progestins has an adverse effect on serum lipid levels, and these lipid effects have raised the question of whether combined estrogen-progestin therapy increases the risk of coronary disease compared with the use of estrogen alone. METHODS: We conducted a population-based, case-control study among enrollees of Group Health Cooperative of Puget Sound. Cases were postmenopausal women who sustained an incident fatal or nonfatal myocardial infarction in 1986 through 1990. Controls were a stratified random sample of female Group Health Cooperative enrollees frequency matched to the cases by age and calendar year. We reviewed the medical records of the 502 cases and 1193 controls and conducted brief telephone interviews with consenting survivors. The health maintenance organization's computerized pharmacy database was used to ascertain the use of postmenopausal hormones. For the primary analysis of current use, we classified women into one of three groups: (1) nonusers of hormones; (2) users of estrogens alone; or (3) users of combined therapy including both estrogens and progestins. Each group of hormone users was compared with nonusers. RESULTS: After adjustment for potential confounding factors, the risk ratio of myocardial infarction associated with current use of estrogens alone was 0.69 (95% confidence interval, 0.47 to 1.02); and the risk ratio of myocardial infarction associated with current use of combined therapy was 0.68 (95% confidence interval, 0.38 to 1.22). Duration of combined-therapy use was relatively short, averaging less than 2 years in cases and controls. CONCLUSIONS: In this case-control study, the reduced risk of myocardial infarction associated with the use of estrogens alone was consistent with previous observational studies. Although the 95% confidence interval only excluded a risk above 1.22, the current use of combined therapy was not associated with an adverse effect on the incidence of myocardial infarction in postmenopausal women.
B M Psaty; S R Heckbert; D Atkins; R Lemaitre; T D Koepsell; P W Wahl; D S Siscovick; E H Wagner
Related Documents :
22849745 - Intracellular human papillomavirus e6, e7 mrna quantification predicts cin 2+ in cervic...
15284085 - Contrasting effects of oral versus transdermal estrogen on serum amyloid a (saa) and hi...
18677155 - Cognitive changes after menopause: influence of estrogen.
10862265 - Modification of serum lipids and cardiovascular risk by estrogenic active compounds.
9403465 - Respiratory symptoms, across-shift lung function changes and lifetime exposures of weld...
1306415 - The effect of body fat distribution on cardiovascular risk factors in the population of...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Archives of internal medicine     Volume:  154     ISSN:  0003-9926     ISO Abbreviation:  Arch. Intern. Med.     Publication Date:  1994 Jun 
Date Detail:
Created Date:  1994-07-12     Completed Date:  1994-07-12     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0372440     Medline TA:  Arch Intern Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1333-9     Citation Subset:  AIM; IM    
Department of Medicine, University of Washington, Seattle.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Case-Control Studies
Drug Therapy, Combination
Estrogens / therapeutic use*
Logistic Models
Medroxyprogesterone / therapeutic use*
Myocardial Infarction / epidemiology*
Risk Factors
Grant Support
Reg. No./Substance:
0/Estrogens; 520-85-4/Medroxyprogesterone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Medical, metabolic, and psychological effects of weight cycling.
Next Document:  Comparison of patients' compliance with prescribed oral and inhaled asthma medications.